Interaction Between Non-typhoid Salmonella, Host Microbiota, and Immune System During Acute Infection and Remission

Stool and blood samples from patients with a non-typhoid Salmonella infection will be collected during an observation period of six months and analyzed for changes in the microbiota diversity and composition, mutation rates in the Salmonella strains and the specific immune response evoked by the infection. Findings are compared to healthy individuals and individuals with acute, infectious diarrhea caused by other microorganisms.

Study Overview

• Status: Unknown
• Conditions: Salmonella Infection Non-Typhoid
• Intervention / Treatment: Other: Blood samples; Other: Stool samples; Other: Clinical information

Detailed Description

Infection processes of a non-typhoid Salmonella infection in humans are not well understood and so far, only little research has been conducted in this area. Findings from preclinical studies, using mouse models, attributed a fundamental role in infection control to the gut microbiota and the host immune system (antibody response). In mouse models a non-typhoid Salmonella infection provokes a pronounced antibody response and salmonella-inflicted gut inflammation alters the microbiota diversity and composition in the gut lumen. To date there is only scarce evidence on similar effects in humans.

During the study, longitudinal stool and blood samples will be collected from patients with a non-typhoid Salmonella infection at different study time points (2 weeks, 4 weeks and 6 months after positive Salmonella stool culture) and analyzed for changes in the microbiota, mutation rates in the Salmonella strains and the specific immune response evoked by the infection (e.g. anti-bodies). At each study time point clinical information will be investigated with a questionnaire to assess current symptoms, medication etc. Findings will be compared to healthy individuals and patients with acute, infectious diarrhea caused by other microorganisms than non-typhoid Salmonella.

• Study Type: Observational
• Enrollment (Anticipated): 40

Contacts and Locations

• Study Contact: Name: Benjamin Misselwitz, PD Dr.med.; Phone Number: +41 44 255 1111; Email: benjamin.misselwitz@usz.ch

Study Locations

• Switzerland
  • Zurich, Switzerland, 8091
    • Recruiting
    • Division of Gastroenterology, University Hospital Zurich

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

20 patients with a non-typhoid Salmonella infection, 10 patients with acute, infectious diarrhea without non-typhoid Salmonella infection, 10 healthy individuals

Description

Inclusion Criteria:

General inclusion criteria:

• Signed informed consent.
• Ability to understand and follow study procedures and understand informed consent
• Age 18-75 years.

Inclusion criteria for patients with non-typhoid Salmonella infection (n=20)

• Acute diarrhea (≥3 bowel movements per day for ≤4 weeks)
• Stool cultures positive for non-typhoid Salmonella ≤4 weeks before inclusion

Inclusion criteria for patients with acute, infectious diarrhea without non-typhoid Salmonella infection (n=10)

• Acute diarrhea (≥3 bowel movements per day for ≤4 weeks)
• Stool cultures negative for non-typhoid Salmonella infection within ≤ 4 weeks

Inclusion criteria for healthy volunteers (n=10)

• No symptoms of acute or chronic diarrhea (2 bowel movements per week to 2 per day)

Exclusion Criteria:

• Current use of antibiotics
• Medication with immunosuppressants (e.g. corticoids, biological therapy).
• Major medical/surgical/psychiatric condition requiring ongoing management. Minor well controlled conditions (i.e. medically controlled arterial hypertension, occupational asthma) may be present.
• Major diagnosis known to chronically affect gut microbiota (e.g. inflammatory bowel disease, liver cirrhosis, colon carcinoma, systemic sclerosis).
• Current diagnosis of a hematological disorder (e.g. severe anemia with hemoglobin <7 g/dl, leukemia) or any other absolute contraindication for blood donation.
• Participation in other clinical study interfering with study procedures.
• Inability to understand study procedures in order to provide inform consent.
• Previous participation in the same study.

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Non-typhoid Salmonella infection; Patients with a non-typhoid Salmonella infection. Blood samples, stool samples and clinical information will be collected.	Other: Blood samples; Blood samples will be collected and analyzed at different study time points; Other: Stool samples; Stool samples will be collected and analyzed at different study time points; Other: Clinical information; Clinical information will be collected at different study time points using questionnaires
Acute, infectious diarrhea; Patients with acute, infectious diarrhea without non-typhoid Salmonella infection. Blood samples, stool samples and clinical information will be collected.	Other: Blood samples; Blood samples will be collected and analyzed at different study time points; Other: Stool samples; Stool samples will be collected and analyzed at different study time points; Other: Clinical information; Clinical information will be collected at different study time points using questionnaires
Healthy individuals; Healthy individuals with no symptoms of acute or chronic diarrhea. Blood samples, stool samples and clinical information will be collected.	Other: Blood samples; Blood samples will be collected and analyzed at different study time points; Other: Stool samples; Stool samples will be collected and analyzed at different study time points; Other: Clinical information; Clinical information will be collected at different study time points using questionnaires

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Genomic mutations in non-typhoid Salmonella strains	Analyze the evolution of non-typhoid Salmonella during acute infection and remission in humans. The primary variable of interest is the number of observed genomic mutations in non-typhoid Salmonella strains.	4 weeks after index stool culture

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quantification of non-typhoid Salmonella genes associated with: tissue invasion, antibiotic resistance and virulence factors	Total number of Salmonella genes associated with tissue invasion Total number of antibiotic resistance genes Total number of virulence factor genes	4 weeks after index stool culture
Identification of most frequently mutated surface antigenes of non-typhoid Salmonella	Identification of escape mechanisms of non-typhoid Salmonella (i.e. mutation of surface antigens) to avoid specific immune responses (i.e. antibodies) during acute infection and remission.	4 weeks after index stool culture
Gen Cluster Expression	Identification of Salmonella gene clusters expressed during early phases of infection compared to remission.	2 weeks, 4 weeks and 6 months after index stool culture
Mutated non-typhoid Salmonella strains	Quantification of mutated non-typhoid Salmonella strains that escape specific immune responses.	4 weeks and 6 months after index stool culture
Microbiota changes	Composition (i.e. number of bacteria species identified) and relative diversity of the gut microbial community during acute non-typhoid Salmonella infection and remission. Findings will be compared to changes occurring in the microbiota of healthy individuals and individuals with acute, infectious diarrhea caused by microorganisms other than Salmonella.	2 weeks, 4 weeks and 6 months after index stool culture
Antibody producing cells	Composition (i.e. number of antibody-producing cells) and relative diversity of antibody-producing cells specific for non-typhoid Salmonella.	2 weeks and 4 weeks after index stool culture
Antibody producing B-cell clones	Number of antibody-producing cell clones (and their corresponding antibodies) against non-typhoid Salmonella isolated from peripheral blood B cells of subjects during remission. Measured variable: Number of Salmonella-specific B-cells per ml blood 4 weeks after infection.	4 weeks after index stool culture
Antibody repertoire	Identification of the antibody repertoire against non-typhoid Salmonella during acute infection in peripheral blood. Measured variable: Antibody titers against various non-typhoid Salmonella strains.	2 weeks and 4 weeks after index stool culture
Antigen- Antibody recognition	Number of antigens of non-typhoid Salmonella recognized by the antibodies isolated from the previous endpoint.	4 weeks and 6 months after index stool culture
Development of irritable bowel syndrome	Number of patients who develop an irritable bowel syndrome after a non-typhoid Salmonella infection.	End of observational period (6 months)

Collaborators and Investigators

• Sponsor: University of Zurich
• Investigators: Principal Investigator: Benjamin Misselwitz, PD Dr.med., Division of Gastroenterology, University Hospital Zurich Zurich, Switzerland, 8091

Study record dates

Study Major Dates

• Study Start (ACTUAL): June 15, 2018
• Primary Completion (ANTICIPATED): January 31, 2020
• Study Completion (ANTICIPATED): January 31, 2020

Study Registration Dates

• First Submitted: March 1, 2018
• First Submitted That Met QC Criteria: April 3, 2018
• First Posted (ACTUAL): April 11, 2018

Study Record Updates

• Last Update Posted (ACTUAL): July 3, 2018
• Last Update Submitted That Met QC Criteria: July 2, 2018
• Last Verified: June 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Enterobacteriaceae Infections; Infections; Communicable Diseases; Salmonella Infections
• Other Study ID Numbers: SALMONELLA Study

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No